Karachi: Abbott Laboratories (Pakistan) Limited has reported substantial financial growth for the year 2024, marking a significant recovery from previous fiscal challenges. The company's profitability ratios reveal a gross profit margin of 29.0%, a notable increase from the previous year's 21.3%. Furthermore, the net profit margin has risen to 7.7% from 0.5% in 2023, indicating a strong rebound in financial performance. These figures are reflective of the pharmaceutical company's strategic direction and operational efficiency.
The company's leadership, headed by Chairman Ehsan Ali Malik and CEO Syed Anis Ahmed, continues to play a pivotal role in driving the company forward. Ehsan Ali Malik, an influential figure in the business community, also holds directorial positions at Standard Chartered Bank (Pakistan) Limited, Friesland Campina Engro Pakistan Limited, and Gul Ahmed Textile Mills Limited. His extensive experience, including previous roles at Unilever, underscores his capability to steer Abbott Laboratories (Pakistan) Limited towards sustained growth.
Syed Anis Ahmed, the CEO, brings over 25 years of experience in finance and commercial roles. His leadership has been instrumental in addressing industry challenges, as evidenced by his past roles with the American Business Council and Pharma Bureau. Ahmed's current involvement with the Overseas Investors' Chamber of Commerce and Industry (OICCI) highlights his continued influence in the sector.
The financial analysis shows a robust return on equity at 22.1%, a substantial increase from 1.4% in 2023. Similarly, the return on assets improved to 13.9% from 0.7%, reflecting better asset utilization. Liquidity ratios also depict a healthy financial position, with the current ratio at 1.99 and a quick ratio of 1.08, both indicating strong short-term financial stability.
Board committee attendance records reveal high engagement levels, particularly in the Audit Committee, chaired by Independent Director Mohsin Ali Nathani. Nathani, with a vast banking background, has overseen full attendance in meetings, ensuring stringent financial oversight. The Human Resource and Remuneration and Risk Management Committees also reported full attendance by key members, underscoring the board's commitment to governance and risk management.
According to information available from the Pakistan Stock Exchange (PSX), Abbott Laboratories (Pakistan) Limited's market capitalization has surged to Rs 121,187 million in 2024, up from Rs 45,055 million in 2023. The company's market value per share at the end of the year stood at Rs 1,237.86, a significant increase from Rs 460.21 in the previous year. This growth in market metrics is indicative of investor confidence and the company's successful navigation of market conditions.
The company's contributions to the national exchequer have also increased, amounting to Rs 9,012 million, further demonstrating its economic impact. These financial results highlight Abbott Laboratories (Pakistan) Limited's resilience and strategic prowess in the face of industry challenges, marking a positive outlook for stakeholders and the market at large.